Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring, subsequent repeat doses
Code effective Dec 13, 2024
HCPCS Section
Medical services
M0240 is a valid 2026 HCPCS code meaning Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring, subsequent repeat doses or (Casiri and imdev repeat) for short. HCPCS M0240 has been effective since 12/13/2024 and applies to Pneumococcal/flu vaccine.
|
HCPCS Level II Code Section M - Medical services |
|
| HCPCS Code | M0240 |
|---|---|
| Description |
Long description:
Short description: |
| HCPCS Pricing indicator |
54 - Vaccinations
|
| Multiple pricing indicator |
A - Not applicable as HCPCS priced under one methodology
|
| Coverage code | C - Carrier judgment |
| BETOS2 code | O1G - Immunizations/Vaccinations |
| HCPCS Action code | N - No maintenance for this code |
| Type of service | V - Pneumococcal/flu vaccine |
| Effective date | Effective Dec 13, 2024 |
| Date added | Added Jul 30, 2021 |
| Termination date | Dec 12, 2024 |
1 Two-digit numeric codes are Level I code modifiers copyrighted© by the American Medical Association's Current Procedural Terminology (CPT).
2 BETOS stands for “Berenson-Eggers Type Of Service”
HCPCS Level II codes and descriptors are approved and maintained jointly by the alpha-numeric editorial panel (consisting of CMS, the Health Insurance Association of America, and the Blue Cross and Blue Shield Association). — Updated 6/23/2026
CPT® is a registered trademark of the American Medical Association (AMA). All rights reserved.